Fluvoxamine for the Treatment of Child and Adolescent Depression: An Open Label Trial
,
Abstract
Objective: Major depressive disorder is a severe disorder that has a significant impact on the psychological and social functioning of children and adolescents. Considering current limitations in the treatment of this disorder, the present study was performed to evaluate the efficacy of fluvoxamine in the treatment of children and adolescents with major depressive disorder.Method: In an open trial, the efficacy of fluvoxamine (50-200 mg/d) on children and adolescents with major depressive disorder or dysthymic disorder was evaluated using the 'Children's Depression Inventory', the 'Hamilton Anxiety Rating Scale', the 'Children - Global Assessment Scale', the 'Clinical Global Impression Scale', and the 'Drug Side Effect Questionnaire' at the beginning and 2, 4, and 8 weeks after the beginning of the treatment. The frequency of suicidal ideas was evaluated as well.
Results: Treatment with fluvoxamine caused statistically significant improvement in all of the above scales. The frequency of suicidal ideas decreased from 88.9 percent to zero after 8 weeks. No significant side effects were observed.
Conclusion: Fluvoxamine can be used as a safe and effective drug in the treatment of major depressive disorder and dysthymic disorder of children and adolescents.
Mulrow CD, Williams Jr JW, Trivedi M, Chiquette E, Aguilar C, Cornell JE, et al. Treatment of depression--newer pharmacotherapies. Psychopharmacol Bull 1998; 34: 409-795.
Sadock BJ, Sadock VA. Kaplan and Sadock’s Synopsis of Psychiatry. 9th ed. philadelphia: Lippincott; 2003.
Weller EB, Weller RA, Rowan AB, Svadjian H. Depressive disorders in children and adolescents. In: Lewis M, eds. Child and adolescent psychiatry. A comprehensive textbook. 3th ed. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 771.
Kutcher SP. depression. In: Ryan N, eds. Practical Child and Adolescent Psychopharmacology. Cambridge: Cambridge University Press; 2002. p. 100-102.
Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 85-102.
Wallace AE, Neily J, Weeks WB, Friedman MJ. A Cumulative Meta-Analysis of Selective Serotonin Reuptake Inhibitors in Pediatric Depression: Did Unpublished Studies Influence the Efficacy/Safety Debate? J Child Adolesc Psychopharmacol 2006; 16: 37-58
Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody T, et al. A double- blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997; 54: 1031-1037.
Biederman J, Spencer T, Wilence T. Psychopharmacology. In: Wiener J, Dulcan MK, eds. Textbook of Child and Adolescent Psychiatry 3rd ed. Washington: American Psychiatric publishing Inc; 2004. p. 931-974
Scahill L. selective serotonin reuptake inhibitors for children and adolescents with major derpession: Current controversiesand recommnedations. Issues Ment Health Nurs 2005; 26: 433-450.
Scahill L, Hamrin V, Pachler ME. The Use of Selective Serotonin Reuptake Inhibitors in Children and Adolescents with Major Depression. J Child Adolesc Psychiatr Nurs 2005; 18: 86-89.
DeVane CL, Sallee FR. Serotonin Selective Reuptake Inhibitors in Child and Adolescent Psychopharmacology: A Review of Published Experience. J Clin Psychiatry 1996; 57: 55-66.
Farley RL. Pharmacological Treatment of Major Depressive Disorder in Adolescents. ScientificWorldJournal 2005; 5: 420–426.
Hjalmarsson L, Corcos M, Jeammet P. Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks). Encephale 2005; 31: 309-316.
Myers K, collett B. Rating scales. In: Wiener JM, Dulcan MK, eds. Textbook of child and Adolescent Psychiatry. 3rd ed. Washington: American Psychiatric Pubishing Inc; 2004. p. 149-164.
Nutt D. Management of patients with depression associated with anxiety symptoms. J Clin Psychiatry 1997; 58: 11-16.
Houck C. an open-label pilot study of fluvoxamine for mixed anxiety-depression. Psychopharmacol Bull 1998; 34: 225-227.
Chabannes JP, Douge R, Baro P. Fluvoxamine and anxiety: Efficacy of fluvoxamine on anxiety into double-blind comparative studies among anxio-depressed patients. VIII World Congress of Psychiatry. Athens, Greece; 1989.
Laws D, Ashford JJ, Anstee JA. A multicentre double-blind comparative trial of fluvoxamine versus lorazepam in mixed anxiety and depression treated in general practice. Acta Psychiatrica Scandinavica 1990; 81: 185-189.
Gothelf D, Rubinstein M, Shemesh E, Miller O, Farbstein I, Klein A, et al. Pilot Study: Fluvoxamine Treatment for Depression and Anxiety Disorders in Children and Adolescents with Cancer. J Am Acad Child Adolesc Psychiatry 2005; 44: 1258-1262.
Cheer SM, Figgitt DP. A Review of its Therapeutic Potential in the Management of Anxiety Disorders in Children and Adolescents. Paediatr Drugs 2001; 3: 763-781.
Apter A, Ratzoni G, King RA, Weizman A, Iancu I, Binder M, et al. Fluvoxamine Open- Label Treatment of Adolescent Inpatients with Obsessive-Compulsive Disorder or Depression. J Am Acad Child Adolesc Psychiatry 1994; 33: 342.
Caley CF, PharmD B, Kando JC, PharmD B. SSRI Efficacy-Finding the Right Dose. J Psychiatr Pract 2002; 8: 33-40.
| Files | ||
| Issue | Vol 3 No 4 (2008) | |
| Section | Articles | |
| Keywords | ||
| Adolescents Children Fluvoxamine Major Depressive Disorder Treatment outcome | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
